Dark

Check out our API

FRLN
Freeline Therapeutics Holdings plc
stock NASDAQ

Inactive

Feb 16, 2024

6.48USD0.000%(0.00)5,663

Pre-market

0.00USD-100.000%(-6.48)0

After-hours

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Jan 11, 2022

10:38AM EST 52 Weeks High And Low Article Benzinga

Jan 7, 2022

01:07PM EST Benzinga's Top Ratings Upgrades, Downgrades For January 7, 2022 Benzinga

01:05PM EST Redburn Partners Upgrades Freeline Therapeutics to Buy Benzinga

Jan 6, 2022

04:01PM EST Freeline Announces Inducement Grants Under Nasdaq Listing Rule GlobeNewswire Inc

07:05AM EST Freeline Announces FDA Clearance Of Investigational New Drug Application For FLT201 For Gaucher Disease Type 1 Benzinga

07:00AM EST FLT201 is the first AAV gene therapy program to enter the clinic for GaucherdiseaseType1 GlobeNewswire Inc

Jan 4, 2022

04:01PM EST Freeline To Participate In Conferences During January 2022 GlobeNewswire Inc

Dec 14, 2021

04:31PM EST 16:31 Tuesday, December 14, 2021Wedbush (RTTNews) - Wedbush Reiterates Freeline Therapeutics Holdings plc (FRLN) At Outperform With $10 Down From $12 Price Target RTTNews

Dec 13, 2021

05:45PM EST UPDATE: Freeline Sees Proposed Reduction In Workforce Decreasing Capex By $4.7M-$5.1M In 2022, $7M-$7.7M In 2023 Benzinga

05:44PM EST UPDATE: Freeline Sees Proposed 25% Reduction In Workforce Benzinga

05:41PM EST UPDATE: Freeline Therapeutics Sees Data From All Its Programs By Mid 2022 Benzinga

05:41PM EST UPDATE: Freeline Sees 'Promising execution in the clinic with programs in hemophilia B, Fabry disease and Gaucher disease' Benzinga

05:40PM EST Freeline Therapeutics Outlines 2022 Corporate Priorities, Guidance Benzinga

05:40PM EST Promising execution in the clinic with programs in hemophilia B, Fabry disease and Gaucher disease; potential to deliver transformative therapies driven by Freelines differentiated platform GlobeNewswire Inc

09:28AM EST Freeline Highlights Presentation Of Long-Term Follow-Up Data From Phase 1/2 B-AMAZE Trial In Hemophilia B At 2021 ASH Annual Meeting And Announces Early Initiation of Phase 1/2 B-LIEVE Dose-Confirmation Trial Benzinga

09:01AM EST B-AMAZE long-term follow up data demonstrate sustained FIX expressionup to 3.5 years; potential for expression levels in the normal range with relatively low vector doses GlobeNewswire Inc

Dec 6, 2021

04:01PM EST Freeline Announces Inducement Grants Under Nasdaq Listing Rule GlobeNewswire Inc

Nov 30, 2021

04:03PM EST Benzinga's Top Ratings Upgrades, Downgrades For November 29, 2021 Benzinga

Nov 29, 2021

07:18AM EST BTIG Initiates Coverage On Freeline Therapeutics with Buy Rating, Announces Price Target of $10 Benzinga

Nov 23, 2021

04:01PM EST Freeline to Participate in Evercore ISI 4th Annual HealthCONx GlobeNewswire Inc

Nov 10, 2021

04:01PM EST Freeline to Participate in Stifel 2021 Virtual Healthcare Conference GlobeNewswire Inc

12:33PM EST Freeline Therapeutics Touts Encouraging Data From Fabry Disease Program Benzinga

Nov 3, 2021

04:01PM EDT Freeline Announces Inducement Grants Under Nasdaq Listing Rule GlobeNewswire Inc

Sep 9, 2021

07:36AM EDT Freeline Announces Orphan Drug Designations For FLT201 For Gaucher Disease RTTNews

07:24AM EDT Freeline Announces Orphan Drug Designations for FLT201 for the Treatment of Gaucher Disease Benzinga

07:00AM EDT Freeline Announces Orphan Drug Designations for FLT201 for the GlobeNewswire Inc

Sep 7, 2021

07:00AM EDT Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the Company or Freeline), a clinical-stage biotechnology company developing transformative AAV-mediated gene therapies for patients suffering from inherited systemic debilitating diseases, today announced that Chief Executive Officer Michael Parini is scheduled to present at the following virtual investor conferences: GlobeNewswire Inc

Aug 18, 2021

07:48AM EDT 10 Biggest Price Target Changes For Wednesday Benzinga

06:24AM EDT HC Wainwright & Co. Maintains Buy on Freeline Therapeutics, Lowers Price Target to $20 Benzinga

Aug 17, 2021

10:09AM EDT Benzinga's Top Ratings Upgrades, Downgrades For August 17, 2021 Benzinga

09:27AM EDT JP Morgan Downgrades Freeline Therapeutics to Neutral, Lowers Price Target to $8 Benzinga

08:28AM EDT The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business Benzinga

Aug 16, 2021

07:06AM EDT Freeline Therapeutics Reports Six Months Ended June EPS $(2.10) Up From $(3.51) YoY Benzinga

07:05AM EDT Freeline Appoints Michael J. Parini as Chief Executive Officer Benzinga

07:00AM EDT On track for three programs in the clinic by year end; trial site initiation for FLT180a for Hemophilia B and FLT201 for Gaucher disease Type 1 expected by year end; program for FLT190 for Fabry disease progressing GlobeNewswire Inc

Aug 13, 2021

06:30AM EDT Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the Company or Freeline), a clinical-stage biotechnology company developing transformative AAV-mediated gene therapies for patients suffering from inherited systemic debilitating diseases, today announced the Company will provide a corporate update and report second quarter 2021 financial results on Monday, August 16. GlobeNewswire Inc

Aug 12, 2021

02:55PM EDT FDA Access Data Website Shows Orphan Drug Designation For Freeline Therapeutics Titled 'Recombinant adeno-associated viral vector serotype S3 containing codon optimised expression cassette encoding human beta-glucocerebrosidase variant' Benzinga

08:09AM EDT The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma Benzinga

Aug 11, 2021

08:14AM EDT The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering Benzinga

Aug 10, 2021

07:55AM EDT The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts Benzinga

Jul 28, 2021

07:33AM EDT The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal Benzinga

Jul 27, 2021

11:13AM EDT The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts Benzinga

Jul 23, 2021

07:45AM EDT The Daily Biotech Pulse: Acorda Spikes On Distribution Deal, Alzamend Soars On Data, Pfizer-BioNTech To Supply More Vaccine Doses, 3 IPOs Benzinga

Jul 21, 2021

07:52AM EDT The Daily Biotech Pulse: J&J, Novartis Report Solid Results, Chembio Soars On COVID Test Order, Lumos Signals Clinical Trial Delay Benzinga

Jul 19, 2021

03:22PM EDT Freeline Therapeutics shares were trading higher. Not seeing any company-specific news to justify the recent price action. Benzinga

Jul 8, 2021

07:45AM EDT The Daily Biotech Pulse: Priority Review For Amgen's Asthma Treatment, Evaxion Reports Positive Skin Cancer Readout, Quidel Recalls Lyra COVID-19 Test Benzinga

Jun 30, 2021

04:01PM EDT Appointment of Chief Technical Operations Officer James Bircher continues evolution of leadership team to execute across near- and long-term priorities GlobeNewswire Inc

07:29AM EDT The Daily Biotech Pulse: COVID Disappointments For Altimmune And Angion, Brickell Jumps On Hyperhidrosis Study Updates, 2 IPOs Benzinga

Jun 16, 2021

07:11AM EDT Freeline Doses Second Patient In Phase 1/2 MARVEL-1 Clinical Trial For Fabry Disease RTTNews

07:00AM EDT Freeline Doses Second Patient of Phase1/2 MARVEL-1 GlobeNewswire Inc

May 28, 2021

10:21AM EDT Mid-Morning Market Update: Markets Open Higher; Big Lots Posts Upbeat Q1 Profit Benzinga

May 19, 2021

10:06AM EDT Benzinga's Top Ratings Upgrades, Downgrades For May 19, 2021 Benzinga

06:15AM EDT HC Wainwright & Co. Initiates Coverage On Freeline Therapeutics with Buy Rating, Announces Price Target of $30 Benzinga

May 18, 2021

12:16PM EDT Benzinga's Top Ratings Upgrades, Downgrades For May 6, 2021 Benzinga

May 17, 2021

04:09PM EDT Freeline Therapeutics Q1 EPS $(0.98) Up From $(1.85) YoY Benzinga

04:02PM EDT FLT190 Phase1/2 dose-finding study in Fabry disease on track to dose additional patients; Company to present data by year-end GlobeNewswire Inc

May 12, 2021

07:00AM EDT Freeline to Participate at the 2021 RBC Capital Markets Global GlobeNewswire Inc

May 11, 2021

07:00AM EDT Freeline Presents Data Highlighting Platform Technology at the GlobeNewswire Inc

May 6, 2021

10:06AM EDT Benzinga's Top Ratings Upgrades, Downgrades For May 6, 2021 Benzinga

07:15AM EDT Guggenheim Initiates Coverage On Freeline Therapeutics with Buy Rating, Announces Price Target of $17 Benzinga

Apr 21, 2021

04:01PM EDT Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the Company or Freeline), a clinical-stage biotechnology company developing transformative AAV-mediated gene therapies for patients suffering from inherited systemic debilitating diseases today announced participation in the following virtual investor conferences: GlobeNewswire Inc

Apr 6, 2021

08:51AM EDT Morgan Stanley Maintains Overweight on Freeline Therapeutics, Lowers Price Target to $22 Benzinga

Mar 31, 2021

04:05PM EDT Freeline Therapeutics Reports FY20 EPS $(6.81) Up From $(8.49) YoY Benzinga

04:02PM EDT Plans to have three AAV gene therapy programs in the clinic by year-end 2021 GlobeNewswire Inc

07:41AM EDT The Daily Biotech Pulse: Pfizer Vaccine 100% Effective In Adolescents, Equillium Readout, Amgen Goes Shopping, Achilles IPO Benzinga

Mar 30, 2021

04:01PM EDT Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the Company or Freeline), a clinical-stage biotechnology company developing transformative gene therapies for patients suffering from inherited systemic debilitating diseases, today announced that the Company will attend the following virtual investor conferences: GlobeNewswire Inc

08:06AM EDT The Daily Biotech Pulse: Wave Life Sciences Pulls Plug On 2 Assets, Amarin's Vascepa Snags European Approval, Biocept Jumps On Earnings Benzinga

Mar 23, 2021

10:04AM EDT Benzinga's Top Ratings Upgrades, Downgrades For March 23, 2021 Benzinga

06:34AM EDT Mizuho Initiates Coverage On Freeline Therapeutics with Buy Rating, Announces Price Target of $27 Benzinga

Mar 11, 2021

07:17AM EST Freeline Appoints Colin Love To Board RTTNews

07:00AM EST Freeline Appoints Colin Love, PhD to Board of Directors GlobeNewswire Inc

Mar 9, 2021

09:17AM EST The Daily Biotech Pulse: Regulatory Setback For Acadia, Lilly Forges Diabetes Antibody Treatment Collaboration, Aytu's Positive COVID-19 Data Benzinga

Mar 4, 2021

08:12AM EST The Daily Biotech Pulse: FDA Nod For Pfizer, Kiniksa Rises On Commercialization Pact With Regeneron, Bio-Techne To Buy Diagnostic Company Benzinga

Mar 2, 2021

01:18PM EST Stifel Initiates Coverage On Freeline Therapeutics with Buy Rating, Announces Price Target of $21 Benzinga

07:00AM EST Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the Company or Freeline), a clinical-stage biotechnology company developing transformative gene therapies for patients suffering from inherited systemic debilitating diseases, announced today that Theresa Heggie, Chief Executive Officer, will present a company overview at the following virtual investor conferences in March: GlobeNewswire Inc

Feb 16, 2021

07:22AM EST A Peek Into The Markets: US Stock Futures Rise Ahead Of Occidental Petroleum, Devon Energy Earnings Benzinga

07:12AM EST Freeline Names Michael Parini President, CEO Benzinga

07:00AM EST Michael J. Parini joins from Vertex as President and Chief Operating Officer complementing recent General Counsel and Investor Relations appointments GlobeNewswire Inc

Feb 9, 2021

07:30AM EST Aquestive Therapeutics Strengthens Board of Directors with GlobeNewswire Inc

01:47AM EST ATHE Gets Funded For Parkinson's Research, No Safety RTTNews

Feb 8, 2021

04:01PM EST Data demonstrate potential of FLT201 to deliver sustained levels of -glucocerebrosidase (GCase) variant 85, a proprietary engineered GCase that penetrates target tissues in Gaucher disease GlobeNewswire Inc

12:47PM EST Freeline Therapeutics To Start FLT180a Dose Confirmation Study In Hemophilia B By 2021 End Benzinga

07:00AM EST Targeting initiation of dose confirmation trial by end of 2021 with data readout byend of 2022 GlobeNewswire Inc

06:36AM EST UPDATE: Freeline Therapeutics Initiation Of Phase 3 Pivotal Trial Targeted By Mid-2023, With Data Readout And BLA Filing Targeted By End Of 2024 Benzinga

06:35AM EST Freeline Therapeutics Updates Clinical Development Plan for its FLT180a Hemophilia B Program; Targeting Initiation Of Dose Confirmation Trial By End Of 2021 With Data Readout By End Of 2022 Benzinga

Jan 26, 2021

07:00AM EST Freeline to Present Data at the 2021 Virtual Congress of the GlobeNewswire Inc

Jan 4, 2021

07:00AM EST Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the Company or Freeline), a clinical-stage, fully integrated, next generation, systemic AAV-based gene therapy company with the ambition of transforming the lives of patients suffering from inherited systemic debilitating diseases, today announced they will participate virtually at conferences during January 2021. GlobeNewswire Inc

Dec 14, 2020

07:02AM EST Freeline Reports Updated Data From Phase 1/2 B-AMAZE Trial In Hemophilia B; Says 'Long-term follow up data show durable FIX activity out to almost 3 years' Benzinga

07:00AM EST Updated dose-ranging data demonstrate potential for full normalization of FIX activity GlobeNewswire Inc

Nov 25, 2020

09:49AM EST Redburn Initiates Coverage On Freeline Therapeutics with Neutral Rating Benzinga

Nov 19, 2020

07:00AM EST Freeline to present at the 3rd Annual Evercore ISI Health CONx GlobeNewswire Inc

Nov 18, 2020

07:30AM EST The Daily Biotech Pulse: Kazia Jumps On Data Readout, Clinical Hold On Cellectis' Blood Cancer Study Lifted Benzinga

Nov 2, 2020

07:00AM EST Freeline appoints Mark Baldry as Chief Commercial Officer GlobeNewswire Inc

Oct 30, 2020

07:00AM EDT - Updated data on analytical technologies for determining the proportion of AAV capsids containing full-length vector genomes GlobeNewswire Inc

Oct 29, 2020

05:06PM EDT Freeline Therapeutics H1 Net Loss $33.264M vs $24.654M In Same Period Last Year Benzinga

Sep 29, 2020

07:00AM EDT Freeline to participate in Chardans 4th Annual GlobeNewswire Inc

Sep 28, 2020

07:05AM EDT Freeline Announces Promotion Of Romuald Corbau, Ph.D. To Chief Scientific Officer Benzinga

07:00AM EDT Freeline announces promotion of Romuald Corbau, Ph.D. to Chief GlobeNewswire Inc

Sep 25, 2020

07:00AM EDT Freeline to participate in Chardans 4th Annual GlobeNewswire Inc

Sep 23, 2020

07:12AM EDT Freeline Therapeutics Announces Supply Agreement With Thermo Fisher Scientific RTTNews

07:06AM EDT Freeline Announces Supply Agreement With Thermo Fisher Scientific For Haemophilia B Program Benzinga

07:00AM EDT Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the Company or Freeline), a clinical stage, fully-integrated, next generation, systemic, AAV-based gene therapy company with the ambition of transforming the lives of patients suffering from inherited systemic debilitating diseases, today announces their supply agreement with Thermo Fisher Scientific Inc. (Thermo Fisher). GlobeNewswire Inc

Sep 1, 2020

10:53AM EDT Wedbush Initiates Coverage On Freeline Therapeutics with Outperform Rating, Announces Price Target of $28 Benzinga

10:50AM EDT Evercore ISI Group Initiates Coverage On Freeline Therapeutics with Outperform Rating, Announces Price Target of $32 Benzinga

10:36AM EDT Morgan Stanley Initiates Coverage On Freeline Therapeutics with Overweight Rating, Announces Price Target of $28 Benzinga

10:36AM EDT CORRECTION: Morgan Stanley Earlier Initiated Coverage On Freeline Therapeutics With An Overweight Rating And $28 Price Target Benzinga

09:47AM EDT Benzinga's Top Upgrades, Downgrades For September 1, 2020 Benzinga

05:33AM EDT JP Morgan Initiates Coverage On Freeline Therapeutics with Overweight Rating, Announces Price Target of $27 Benzinga

Aug 30, 2020

08:24AM EDT The Week Ahead In Biotech (Aug. 30- Sept. 5): Bristol-Myers Squibb FDA Decision, Adcom Review For Glaxo, Amarin Vascepa Hearing Benzinga

Aug 7, 2020

01:08PM EDT Freeline Therapeutics Holdings Shares Open For Trade At $18.50; IPO Priced At $18/Share Benzinga

09:19AM EDT Freeline Therapeutics Holdings Expected To Open For Quote At 10:35 a.m. EDT, Expected To Open For Trade After 10:45 a.m. EDT; IPO Priced At $18/Share Benzinga

08:01AM EDT Benzinga Pro's Top 5 Stocks To Watch For Fri., Aug. 7, 2020: WKHS, GO, CGC, FRLN, KNDI Benzinga

02:50AM EDT Freeline Announces Pricing of Initial Public Offering GlobeNewswire Inc

Aug 3, 2020

06:30AM EDT Freeline Launches Roadshow for Initial Public Offering GlobeNewswire Inc

Share